Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Annette Hasenburg Prof., Dr, med
Annette Hasenburg Prof., Dr, med Advisory Board
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · December 19, 2023

GSK525762 Plus Fulvestrant for HR+/HER2− Advanced or Metastatic Breast Cancer

Clinical Cancer Research

 

 Save  Recommend
 Share

Additional Info

Clinical Cancer Research
A Phase I/II Study of GSK525762 Combined With Fulvestrant in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced or Metastatic Breast Cancer
Clin. Cancer Res 2023 Nov 22;[EPub Ahead of Print], DW Cescon, J Hilton, S Morales Murilo, RM Layman, T Pluard, B Yeo, IH Park, L Provencher, SB Kim, YH Im, A Wyce, AS Krishnatry, K Hicks, Q Zhang, O Barbash, A Khaled, T Horner, A Dhar, M Oliveira, JA Sparano

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated